Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07803822) titled 'Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Shanghai Minwei Biotechnology Co., Ltd
Condition:
Mixed Dyslipidemia
Intervention:
Drug: MWX203
Drug: Inclisiran Sodium Injection
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: September 25, 2026
Target Sample Size: 216
Countries of Recru...